eFFECTOR Therapeutics, Inc. (EFTR)

Market Cap	941.00 -99.8%
Revenue (ttm)	n/a
Net Income	-34.63M
EPS	-12.42
Shares Out	4.70M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	9,639
Open	0.0002
Previous Close	0.0002
Day's Range	0.0002 - 0.0002
52-Week Range	0.0001 - 0.0200
Beta	0.96
RSI	48.12
Earnings Date	n/a

About eFFECTOR Therapeutics

eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. The company’s lead product candidate includes Zotatifin, an inhibitor of eIF4A, which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as has completed Phase 2 clinical trial in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. It also develops Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinica...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 14
• Stock Exchange: OTCMKTS
• Ticker Symbol: EFTR